CommentaryProstateNov 12, 2026

ACS now recommends PSA screening. The pathway after the PSA is our job.

For the first time since 2010, the American Cancer Society makes a direct recommendation to screen. Here is what changed, the evidence behind it, and how it lines up against AUA/SUO and USPSTF.

The author selected the evidence, set the argument and edited the final text. AI tools assisted with drafting and formatting. Every figure was checked against its source.

Illustration: a net holds a shark while a school of small fish swims freely through the mesh

The ACS guideline published today in CA: A Cancer Journal for Clinicians moves the society from shared decision-making without a screening recommendation to biennial PSA-based screening for average-risk men aged 50 to 69, and annual screening from 45 for Black men and men with a strong family history. The guideline development group concluded there is moderate certainty that benefits outweigh harms.

For urologists, the headline is less about the PSA and more about everything that follows it. The guideline builds harm reduction directly into the recommendation: confirm an elevated PSA before acting, use MRI and/or a validated biomarker before biopsy, and offer active surveillance first for low-risk disease.

Figure 1
Prostate cancer screening guidelines, side by side
UrologyWatch
ACS 2010Previous ACS 2026Released Nov 12, 2026 AUA/SUO2023, amended 2026 USPSTF2018, update in progress
Core stance Informed decision
No direct recommendation to screen
Screen
Direct recommendation, after patient understands benefits, limitations and harms
Shared decision
Offer regular screening; PSA as first test
Grade C
Individual decision after discussion with a clinician
Average risk Discussion at 50 50 to 69, every 2 years Baseline PSA may be offered at 45 to 50; every 2 to 4 years at 50 to 69, personalized 55 to 69; interval not specified
Higher risk Discussion at 45 (Black men, FDR before 65); 40 if several FDRs diagnosed early Annual from 45 to 69: Black men; FDR before 65; multiple FDRs. Biennial from 45 if one FDR at 65 or older Offer screening from 40 to 45: Black ancestry, germline mutations, strong family history Higher risk acknowledged; no separate schedule
Older men Not with life expectancy under 10 years 70 to 74 individualized; not recommended at 75+ or LE under 10 y. Exception: honoring a very healthy man's request at 75 to 79, especially with a rising PSA, may be reasonable after discussing uncertain benefit and greater harms Personalize or stop based on age, PSA, risk, life expectancy, health Grade D
Against routine screening at 70+
Elevated PSA Not specified at this level Threshold ≥3.0 ng/mL (45 to 69), ≥6.5 (70 to 74). Repeat in 2 wk to 3 mo; if confirmed, offer MRI and/or validated biomarker before biopsy Repeat PSA before further testing; MRI before biopsy may be used; biomarkers for risk reassessment Not addressed
Low-risk cancer Not addressed Offer active surveillance as initial management Addressed in separate localized PCa guideline Surveillance noted to reduce overtreatment
FDR, first-degree relative; LE, life expectancy. Sources: ACS 2026 (Hoffman et al., CA Cancer J Clin); ACS 2010; AUA/SUO Early Detection guideline (2026 amendment); USPSTF 2018.

The evidence that moved ACS

ACS built the update on a commissioned systematic review, CISNET modeling of screening strategies, and long follow-up of the randomized trials. The guideline group judged that the evidence now gives moderate certainty that benefits outweigh harms for average-risk men. Certainty is not uniform across the recommendations: starting at 45 for Black men rests on low-certainty evidence, and the annual interval for Black men and the family-history schedules are consensus statements. The key change since 2010 is follow-up length: as the trials matured, the absolute benefit grew and the number of men needed to invite and diagnose fell.

TrialDesignResult cited by ACS
ERSPC, 23-yrPubMedMen 55 to 69 (core group), PSA every 2 to 4 yr, 7 countriesPCSM RR 0.87 (0.80 to 0.95)
ARR 0.22%; NNI 456, NND 12
Göteborg-1, 22-yrPubMed 3542213420,000 men 50 to 64; biennial PSA to age 71PCSM RR 0.71 (0.55 to 0.91)
CAP, 15-yrPubMed 38581198415,357 men 50 to 69; single PSA invitation, 36% uptakePCSM RR 0.92 (0.85 to 0.99)
ARR 0.09%
PLCO, 15-yrPubMed76,683 men 55 to 74; six annual PSA testsNo mortality difference; ~90% control-arm PSA testing and low biopsy compliance
ERSPC and PLCO reconciliationPubMed 28869989CISNET modeling for contamination and lead timeCompatible benefit in both trials vs no screening

Two details are worth having ready. In ERSPC, the relative reduction attenuated from 9 to 23 years because deaths accrued after screening stopped, yet the absolute reduction tripled (0.07% to 0.22%) and NNI fell from 1,410 to 456. ERSPC also showed roughly a 42% reduction in metastatic disease at 12 years across four centers. CAP shows that even a single invitation to PSA screening can reduce prostate cancer mortality, although the absolute benefit is small. Repeated screening offers more opportunities for early detection, but screening intensity must be balanced against cumulative harms.

Evidence gap. ERSPC and CAP did not report the number of Black participants. The annual-from-45 recommendation for Black men rests on CISNET modeling and observed disparities (67% higher incidence, nearly double mortality) more than on randomized data. ACS also notes false-negative MRI is more common in Black men.

The harm-reduction pathway

The 2012 USPSTF D recommendation reflected an unfavorable assessment of screening benefits and harms in an era when reflex biopsy, systematic transrectal sampling and treatment of low-risk cancers were common. The downstream diagnostic and management pathways have since changed substantially, and ACS cites a different evidence base for the pathway it now recommends.

Also cited: the German PROBASE trial, which is testing a baseline PSA at 45 and found DRE adds little in screening; ACS does not recommend DRE as a screening test.

What this means for urology practices

The ACS update is a welcome correction. Screening done well catches the sharks and leaves the minnows alone. The PSA is the entry point; the pathway behind it determines whether we help or harm.

Key references

  1. Hoffman RM, Wolf AMD, Etzioni RD, et al. American Cancer Society guideline for the early detection of prostate cancer, 2026. CA Cancer J Clin. 2026. doi:10.3322/caac.70112
  2. Roobol MJ, de Vos II, Månsson M, et al. European Study of Prostate Cancer Screening: 23-year follow-up. N Engl J Med. 2025;393:1669-1680. PubMed
  3. Frånlund M, et al. Results from 22 years of followup in the Göteborg randomized prostate cancer screening trial. J Urol. 2022;208:292-300. PubMed
  4. Martin RM, et al. PSA screening and 15-year prostate cancer mortality: secondary analysis of the CAP trial. JAMA. 2024;331:1460-1470. PubMed
  5. Pinsky PF, et al. Extended mortality results for prostate cancer screening in the PLCO trial with median follow-up of 15 years. Cancer. 2017;123:592-599. PubMed
  6. Tsodikov A, et al. Reconciling the effects of screening on prostate cancer mortality in the ERSPC and PLCO trials. Ann Intern Med. 2017;167:449-455. PubMed
  7. Griffin JC, et al. PSA-based screening for prostate cancer: a systematic review to inform an American Cancer Society guideline. Cancer. 2026. PubMed
  8. Drost FH, et al. Prostate MRI, with or without MRI-targeted biopsy, and systematic biopsy for detecting prostate cancer. Cochrane Database Syst Rev. 2019. PubMed
  9. Fazekas T, et al. Magnetic resonance imaging in prostate cancer screening: a systematic review and meta-analysis. JAMA Oncol. 2024;10:745-754. PubMed
  10. Auvinen A, et al. Prostate cancer screening with PSA, kallikrein panel, and MRI: the ProScreen randomized trial. JAMA. 2024;331:1452-1459. PubMed
  11. Palsdottir T, et al. Stockholm3-MRI population-based prostate cancer screening study: two-year follow-up. Ann Intern Med. 2026;179:988-995. PubMed
  12. Newcomb LF, et al. Long-term outcomes in patients using protocol-directed active surveillance for prostate cancer (Canary PASS). JAMA. 2024;331:2084-2093. PubMed
  13. Hamdy FC, et al. Fifteen-year outcomes after monitoring, surgery, or radiotherapy for prostate cancer (ProtecT). N Engl J Med. 2023;388:1547-1558. PubMed
  14. Early Detection of Prostate Cancer: AUA/SUO Guideline (2023, amended 2026). AUA

Disclosures: Dr. Kutikov is a co-founder and co-owner of UrologyWatch.com. He reports consulting/advisory roles with Telix Pharmaceuticals, UroGen Pharma and Insight Medbotics, and equity in Scopia Surgical.

Commentary reflects the author's views. It is written and signed by the author, is separate from the daily ranked edition, and is not medical advice.

Home · About · Archive · Privacy · Terms · © 2026 UrologyMatch, LLC

Follow us@UrologyWatchHQInstagramBlueskyFacebook